Payment overview · 2025
General Payments
$512.26
26 reported records · 16 companies
Healthcare provider profile · identity verified
Devabrata Ganguly, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CLARKSVILLE, TX · NPI 1225077274
Verified facts
What the public records show
CMS Open Payments records show Devabrata Ganguly, M.D. received $512.26 in general payments during 2025 across 26 reported records.
GlaxoSmithKline, LLC. accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 691 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $96.60 | 18.9% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $77.56 | 15.1% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $64.45 | 12.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.08 | 7.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.72 | 6.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.79 | 4.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.25 | 4.3% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $21.83 | 4.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.25 | 3.8% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $18.63 | 3.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.12 | 3.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.05 | 3.3% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $16.67 | 3.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.35 | 3.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.84 | 3.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.07 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $512.26 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $80.94 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $77.56 | 3 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $41.97 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $38.29 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.08 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.08 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.72 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.72 | 2 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 319 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 197 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 139 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
319 | 54 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
139 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
319 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
197 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
24 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
691 | 77 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Potassium Chloride | Potassium Chloride | 1411 | 264 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1398 | 247 |
| Furosemide | Furosemide | 1132 | 214 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1097 | 211 |
| Amlodipine Besylate | Amlodipine Besylate | 1034 | 210 |
| Losartan Potassium | Losartan Potassium | 990 | 207 |
| Gabapentin | Gabapentin | 731 | 162 |
| Eliquis | Apixaban | 691 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 686 | 173 |
| Pantoprazole Sodium | Pantoprazole Sodium | 634 | 143 |
| Carvedilol | Carvedilol | 579 | 118 |
| Lisinopril | Lisinopril | 576 | 128 |
| Metformin Hcl | Metformin Hcl | 556 | 122 |
| Metoprolol Tartrate | Metoprolol Tartrate | 550 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 536 | 123 |
| Tamsulosin Hcl | Tamsulosin Hcl | 441 | 96 |
| Omeprazole | Omeprazole | 407 | 96 |
| Tramadol Hcl | Tramadol Hcl | 404 | 132 |
| Sertraline Hcl | Sertraline Hcl | 391 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 374 | 78 |
| Montelukast Sodium | Montelukast Sodium | 361 | 75 |
| Duloxetine Hcl | Duloxetine Hcl | 343 | 54 |
| Memantine Hcl | Memantine Hcl | 337 | 52 |
| Donepezil Hcl | Donepezil Hcl | 322 | 54 |
| Jardiance | Empagliflozin | 319 | 54 |
| Simvastatin | Simvastatin | 315 | 55 |
| Allopurinol | Allopurinol | 297 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 295 | 58 |
| Januvia | Sitagliptin Phosphate | 291 | 35 |
| Mirtazapine | Mirtazapine | 269 | 51 |
| Valsartan | Valsartan | 267 | 66 |
| Meloxicam | Meloxicam | 266 | 70 |
| Celecoxib | Celecoxib | 264 | 60 |
| Buspirone Hcl | Buspirone Hcl | 253 | 49 |
| Clonazepam | Clonazepam | 251 | 49 |
| Trazodone Hcl | Trazodone Hcl | 243 | 50 |
| Spironolactone | Spironolactone | 239 | 65 |
| Nifedipine Er | Nifedipine | 238 | 46 |
| Ondansetron Hcl | Ondansetron Hcl | 231 | 72 |
| Quetiapine Fumarate | Quetiapine Fumarate | 230 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 226 | 49 |
| Xarelto | Rivaroxaban | 199 | 31 |
| Ozempic | Semaglutide | 197 | 43 |
| Farxiga | Dapagliflozin Propanediol | 196 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 192 | 35 |
| Famotidine | Famotidine | 188 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 183 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 44 |
| Divalproex Sodium | Divalproex Sodium | 180 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 174 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 165 | 59 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 157 | 27 |
| Levetiracetam | Levetiracetam | 155 | 26 |
| Myrbetriq | Mirabegron | 154 | 25 |
| Finasteride | Finasteride | 152 | 35 |
| Prednisone | Prednisone | 145 | 70 |
| Pregabalin | Pregabalin | 144 | 28 |
| Azithromycin | Azithromycin | 142 | 96 |
| Ropinirole Hcl | Ropinirole Hcl | 141 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 139 | 27 |
| Warfarin Sodium | Warfarin Sodium | 139 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 48 |
| Baclofen | Baclofen | 127 | 24 |
| Oxcarbazepine | Oxcarbazepine | 127 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 33 |
| Clonidine Hcl | Clonidine Hcl | 125 | 33 |
| Ezetimibe | Ezetimibe | 124 | 26 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 118 | 20 |
| Lorazepam | Lorazepam | 112 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 109 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 108 | 42 |
| Torsemide | Torsemide | 105 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 99 | 16 |
| Albuterol Sulfate | Albuterol Sulfate | 96 | 20 |
| Glipizide | Glipizide | 96 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 96 | 61 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 96 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 18 |
| Indapamide | Indapamide | 91 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 88 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 88 | 19 |
| Midodrine Hcl | Midodrine Hcl | 87 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 63 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 86 | 31 |
| Oxybutynin Chloride | Oxybutynin Chloride | 86 | 18 |
| Alprazolam | Alprazolam | 85 | 20 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 84 | 23 |
| Novolog Flexpen | Insulin Aspart | 84 | 15 |
| Eszopiclone | Eszopiclone | 82 | 18 |
| Olanzapine | Olanzapine | 82 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 27 |
| Latanoprost | Latanoprost | 78 | suppressed |
| Risperidone | Risperidone | 77 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 58 |
| Amiodarone Hcl | Amiodarone Hcl | 68 | suppressed |
| Irbesartan | Irbesartan | 68 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 11 |
| Bumetanide | Bumetanide | 64 | 15 |
| Enulose | Lactulose | 64 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | suppressed |
| Lovastatin | Lovastatin | 59 | 13 |
| Topiramate | Topiramate | 59 | suppressed |
| Atenolol | Atenolol | 58 | 16 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 58 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 58 | 13 |
| Metformin Hcl Er | Metformin Hcl | 58 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | 33 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 55 | 19 |
| Entresto | Sacubitril/Valsartan | 55 | 12 |
| Meclizine Hcl | Meclizine Hcl | 55 | 19 |
| Sucralfate | Sucralfate | 55 | 16 |
| Digoxin | Digoxin | 54 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 11 |
| Mounjaro | Tirzepatide | 54 | 11 |
| Cephalexin | Cephalexin | 53 | 44 |
| Diltiazem Hcl | Diltiazem Hcl | 52 | 11 |
| Verapamil Er | Verapamil Hcl | 52 | suppressed |
| Klor-Con 10 | Potassium Chloride | 51 | 18 |
| Benazepril Hcl | Benazepril Hcl | 50 | 12 |
| Doxepin Hcl | Doxepin Hcl | 49 | suppressed |
| Klor-Con M20 | Potassium Chloride | 49 | 14 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 48 | 11 |
| Linzess | Linaclotide | 48 | suppressed |
| Hydrocortisone | Hydrocortisone | 47 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 47 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 47 | 14 |
| Calcitriol | Calcitriol | 45 | suppressed |
| Estradiol | Estradiol | 45 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 44 | suppressed |
| Lamotrigine | Lamotrigine | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 33 |
| Loperamide | Loperamide Hcl | 42 | 16 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Fluconazole | Fluconazole | 40 | 31 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 39 | 22 |
| Brimonidine Tartrate | Brimonidine Tartrate | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 20 |
| Primidone | Primidone | 37 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 37 | suppressed |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | 11 |
| Budesonide | Budesonide | 34 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Sotalol | Sotalol Hcl | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 33 | suppressed |
| Febuxostat | Febuxostat | 33 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | 14 |
| Prazosin Hcl | Prazosin Hcl | 33 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 17 |
| Telmisartan | Telmisartan | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 24 |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Clonidine | Clonidine | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | 24 |
| Fluorometholone | Fluorometholone | 27 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Belsomra | Suvorexant | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Buprenorphine | Buprenorphine | 24 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Nystatin | Nystatin | 24 | 18 |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 11 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 17 |
| Prednisolone Acetate | Prednisolone Acetate | 19 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Qulipta | Atogepant | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Livalo | Pitavastatin Calcium | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 16 |
| Metolazone | Metolazone | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Progesterone | Progesterone, Micronized | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Alogliptin | Alogliptin Benzoate | 15 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Famciclovir | Famciclovir | 13 | 13 |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Gocovri | Amantadine Hcl | 13 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Victoza 2-Pak | Liraglutide | 12 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 11 | suppressed |
| Forteo | Teriparatide | 11 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $512.26 · 26 records | GlaxoSmithKline, LLC. | AMYVID, AREXVY, Auvelity, CABENUVA, CAPLYTA, Cologuard Collection Kit, GVOKE HYPOPEN, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JARDIANCE, KISUNLA, Korlym, NURTEC ODT, Onivyde, Ozempic, PIFELTRO, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VERQUVO, VOQUEZNA, YUPELRI, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error